Safety and immunogenicity of an HIV-1 recombinant canarypox vaccine in newborns and infants of HIV-1 infected women

被引：40

作者：

Johnson, DC

McFarland, EJ

Muresan, P

Fenton, T

McNamara, J

Read, JS

Hawkins, E

Bouquin, PL

Estep, SG

Tomaras, GD

Vincent, CA

Rathore, M

Melvin, AJ

Gurunathan, S

Lambert, J

机构：

[1] Sinai Childrens Hosp, Dept Pediat, Chicago, IL 60608 USA

[2] Rosalind Franklin Univ Med & Sci, N Chicago, IL USA

[3] Univ Colorado, Hlth Sci Ctr, Dept Pediat Infect Dis, Denver, CO 80202 USA

[4] Harvard Univ, Sch Publ Hlth, Stat & Data Anal Ctr, Boston, MA 02115 USA

[5] NIAID, Clin Immunol Branch, Div Allergy & Immunol Transplantat, NIH, Bethesda, MD 20892 USA

[6] NIAID, Div Aids, Pharmaceut Affairs Branch, NIH, Bethesda, MD 20892 USA

[7] NICHHD, Pediat Adolescent & Maternal AIDS Branch, NIH, Bethesda, MD 20892 USA

[8] Social & Sci Syst Inc, Silver Spring, MD USA

[9] Univ Maryland, Inst Human Virol, Baltimore, MD 21201 USA

[10] Duke Univ, Med Ctr, Dept Surg, Durham, NC 27710 USA

[11] Duke Univ, Med Ctr, Ctr Virol, Durham, NC 27710 USA

[12] Childrens Hosp Philadelphia, Philadelphia, PA 19104 USA

[13] Sanofi Pasteur, Swiftwater, PA USA

[14] Univ Florida, Hlth Sci Ctr, Jacksonville, FL 32209 USA

[15] Univ Washington, Seattle, WA 98195 USA

[16] Childrens Hosp & Reg Med Ctr, Seattle, WA USA

[17] Inst Child Hlth, London, England

来源：

JOURNAL OF INFECTIOUS DISEASES | 2005年 / 192卷 / 12期

关键词：

D O I：

10.1086/498163

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Pediatric AIDS Clinical Trials Group protocol 326 is a study of 2 formulations of recombinant canarypox ALVAC vaccine (vCP205) against human immunodeficiency virus type 1 (HIV-1). HIV-1-exposed infants were randomized to receive 1 of 2 formulations of vCP205 or placebo at birth and 4, 8, and 12 weeks. The vaccines were safe. Lymphoproliferative responses were detected at >= 2 time points in 44%-56% of vaccinees and none of the placebo recipients. A cytotoxic T lymphocyte response on at least 1 occasion was detected in 62.5% of infants in cohort 1 (10(6.08) median tissue culture dose [TCID50] vaccine formulation) and 44% of infants in cohort 2 (10(6.33) TCID50 vaccine formulation). Rare mucosal immunoglobulin A responses and no measurable vaccine-elicited serum antibodies were detected. In children, vCP205 appeared to be safe and immunogenic.

引用

页码：2129 / 2133

页数：5

共 15 条

[1] POTENTIAL USE OF NONREPLICATING VECTORS AS RECOMBINANT VACCINES [J].

BAXBY, D ;

PAOLETTI, E .

VACCINE, 1992, 10 (01) :8-9

[2] Induction of immune responses to HIV-1 by canarypox virus (ALVAC) HIV-1 and gp120 SF-2 recombinant vaccines in uninfected volunteers [J].

Belshe, RB ;

Gorse, GJ ;

Mulligan, MJ ;

Evans, TG ;

Keefer, MC ;

Excler, JL ;

Duliege, AM ;

Tartaglia, J ;

Cox, WI ;

McNamara, J ;

Hwang, KL ;

Bradney, A ;

Montefiori, D ;

Weinhold, KJ .

AIDS, 1998, 12 (18) :2407-2415

[3] Lymphoproliferative responses to recombinant HIV-1 envelope antigens in neonates and infants receiving gp120 vaccines [J].

Borkowsky, W ;

Wara, D ;

Fenton, T ;

McNamara, J ;

Kang, MH ;

Mofenson, L ;

McFarland, E ;

Cunningham, C ;

Duliege, AM ;

Francis, D ;

Bryson, Y ;

Burchett, S ;

Spector, SA ;

Frenkel, LM ;

Starr, S ;

Van Dyke, R ;

Jimenez, E .

JOURNAL OF INFECTIOUS DISEASES, 2000, 181 (03) :890-896

[4] IMMUNIZATION WITH CANARYPOX VIRUS EXPRESSING RABIES GLYCOPROTEIN [J].

CADOZ, M ;

STRADY, A ;

MEIGNIER, B ;

TAYLOR, J ;

TARTAGLIA, J ;

PAOLETTI, E ;

PLOTKIN, S .

LANCET, 1992, 339 (8807) :1429-1432

[5]

Coutsoudis A, 2004, J INFECT DIS, V189, P2154, DOI 10.1086/420834

[6] Safety of 2 recombinant human immunodeficiency virus type 1 (HIV-1) envelope vaccines in neonates born to HIV-1-Infected women [J].

Cunningham, CK ;

Wara, DW ;

Kang, MH ;

Fenton, T ;

Hawkins, E ;

McNamara, J ;

Mofenson, L ;

Duliege, AM ;

Francis, D ;

McFarland, EJ ;

Borkowsky, W .

CLINICAL INFECTIOUS DISEASES, 2001, 32 (05) :801-807

[7] High-dose recombinant canarypox vaccine expressing HIV-1 protein, in seronegative human subjects [J].

Goepfert, PA ;

Horton, H ;

McElrath, MJ ;

Gurunathan, S ;

Ferrari, G ;

Tomaras, GD ;

Montefiori, DC ;

Allen, M ;

Chiu, YL ;

Spearman, P ;

Fuchs, JD ;

Koblin, BA ;

Blattner, WA ;

Frey, S ;

Keefer, MC ;

Baden, LR ;

Corey, L .

JOURNAL OF INFECTIOUS DISEASES, 2005, 192 (07) :1249-1259

[8] HIV type 1 vaccine-induced T cell memory and cytotoxic T lymphocyte responses in HIV type 1-uninfected volunteers [J].

Gorse, GJ ;

Patel, GB ;

Belshe, RB .

AIDS RESEARCH AND HUMAN RETROVIRUSES, 2001, 17 (12) :1175-1189

[9] A SCREENING-TEST FOR THE DETECTION OF ANTI-HIV-1 IGA IN YOUNG INFANTS [J].

MARTIN, NL ;

RAUTONEN, J ;

CROMBLEHOLME, W ;

RAUTONEN, N ;

WARA, DW .

IMMUNOLOGICAL INVESTIGATIONS, 1992, 21 (01) :65-70

[10]

McFarland EJ, 1998, J IMMUNOL, V161, P513

← 1 2 →